122 related articles for article (PubMed ID: 7013959)
1. Activity of indicine N-oxide in refractory acute leukemia.
Letendre L; Smithson WA; Gilchrist GS; Burgert EO; Hoagland CH; Ames MM; Powis G; Kovach JS
Cancer; 1981 Feb; 47(3):437-41. PubMed ID: 7013959
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular toxicity during the treatment of refractory acute leukemia with indicine N-oxide.
Letendre L; Ludwig J; Perrault J; Smithson WA; Kovach JS
Cancer; 1984 Oct; 54(7):1256-9. PubMed ID: 6590115
[TBL] [Abstract][Full Text] [Related]
3. Indicine-N-oxide: a new antitumor agent.
Poster DS; Bruno S; Penta J; Macdonald JS
Cancer Treat Rep; 1981; 65(1-2):53-6. PubMed ID: 6939484
[TBL] [Abstract][Full Text] [Related]
4. Hepatic failure secondary to indicine N-oxide toxicity. A Pediatric Oncology Group Study.
Cook BA; Sinnhuber JR; Thomas PJ; Olson TA; Silverman TA; Jones R; Whitehead VM; Ruymann FB
Cancer; 1983 Jul; 52(1):61-3. PubMed ID: 6573942
[TBL] [Abstract][Full Text] [Related]
5. High incidence of veno-occlusive disease related to indicine N-oxide in the treatment of refractory adult acute leukemia.
Winton EF; McCue PA
Cancer Treat Rep; 1986 Jul; 70(7):933-4. PubMed ID: 3459576
[No Abstract] [Full Text] [Related]
6. Phase II trial of indicine N-oxide in relapsed acute leukemia of childhood. A report from the Childrens Cancer Study Group.
Miser JS; Smithson WA; Krivit W; Hughes CH; Davis D; Krailo MD; Hammond GD
Am J Clin Oncol; 1992 Apr; 15(2):135-40. PubMed ID: 1553901
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of indicine-N-oxide in children with leukemia and solid tumors: a Pediatric Oncology Group study.
Whitehead VM; Bernstein ML; Vega R; Vats T; Dyment P; Vietti TJ; Krischer J
Cancer Chemother Pharmacol; 1990; 26(5):377-9. PubMed ID: 2208580
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of indicine N-oxide (INDI) in patients with advanced colorectal carcinoma.
Nichols WC; Moertel CG; Rubin J; Schutt AJ; Britell JC
Cancer Treat Rep; 1981; 65(3-4):337-9. PubMed ID: 7016321
[No Abstract] [Full Text] [Related]
9. Indicine N-oxide: clinical use of a pyrrolizidine alkaloid.
King SA; Suffness M; Leyland-Jones B; Hoth DF; O'Dwyer PJ
Cancer Treat Rep; 1987 May; 71(5):517-23. PubMed ID: 3552221
[No Abstract] [Full Text] [Related]
10. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
Paciucci PA; Cuttner J; Holland JF
Semin Oncol; 1984 Sep; 11(3 Suppl 1):36-40. PubMed ID: 6385264
[TBL] [Abstract][Full Text] [Related]
11. Relationship of the reductive metabolism of indicine N-oxide to its antitumor activity.
Powis G; Ames MM; Kovach JS
Res Commun Chem Pathol Pharmacol; 1979 Jun; 24(3):559-69. PubMed ID: 451340
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone, vincristine, and prednisone in adults with relapsed or primarily refractory acute lymphocytic leukemia and terminal deoxynucleotidyl transferase positive blastic phase chronic myelocytic leukemia.
Paciucci PA; Keaveney C; Cuttner J; Holland JF
Cancer Res; 1987 Oct; 47(19):5234-7. PubMed ID: 3476201
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acute leukemia with 5-azacytidine (NSC-102816).
McCredie KB; Bodey GP; Burgess MA; Gutterman JU; Rodriguez V; Sullivan MP; Freireich EJ
Cancer Chemother Rep; 1973; 57(3):319-23. PubMed ID: 4127393
[No Abstract] [Full Text] [Related]
14. Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
Meyer P; Ho AD; Ehninger G; Mjaaland I; Heidemann E; Seither E
Invest New Drugs; 1985; 3(2):203-6. PubMed ID: 3860490
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory acute leukemia with aclacinomycin-A.
Takahashi I; Hara M; Adachi T; Takaoka K; Sakano M; Lai M; Kohi F; Yorimitsu S; Tokioka M; Kitajima K; Kimura I; Sanada H
Acta Med Okayama; 1980 Nov; 34(5):349-54. PubMed ID: 6449134
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of indicine N-oxide in patients with advanced cancer.
Ohnuma T; Sridhar KS; Ratner LH; Holland JF
Cancer Treat Rep; 1982 Jul; 66(7):1509-15. PubMed ID: 7093966
[TBL] [Abstract][Full Text] [Related]
18. [High-dose busulfan with subsequent bone marrow transplantation in poor-risk forms of leukemia].
Urban C; Slavc I; Kaulfersch W; Teubl I
Wien Klin Wochenschr; 1987 Mar; 99(5):144-9. PubMed ID: 3554777
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of succinylated Acinetobacter glutaminase-asparaginase in adult leukemia.
Warrell RP; Arlin ZA; Gee TS; Chou TC; Roberts J; Young CW
Cancer Treat Rep; 1982 Jul; 66(7):1479-85. PubMed ID: 7046929
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
Moore JO; Olsen GA
Semin Oncol; 1984 Sep; 11(3 Suppl 1):41-6. PubMed ID: 6385265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
